Skip to search formSkip to main contentSkip to account menu

MPC-3100

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Discovery of an L-alanine ester prodrug of the Hsp90 inhibitor, MPC-3100.
2011
2011
Abstract A96: Phase 1 study of HSP90 inhibitor MPC-3100 in subjects with refractory or recurrent cancer.
Background: MPC-3100 is an orally-bioavailable, fully-synthetic inhibitor of the molecular chaperone HSP90. HSP90 is important… 
2011
2011
Abstract 3237: Evaluation of the pharmacokinetics and efficacy of a novel pro-drug of the HSP90 inhibitor, MPC-3100, designed with improved solubility
MPC-3100 is a synthetic, orally bioavailable HSP90 inhibitor in clinical development. The low solubility of this compound… 
2011
2011
Abstract 2628: Antitumor activity of MPC-3100, a synthetic Hsp90 inhibitor, in combination with erlotinib and sorafenib
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Introduction: MPC-3100 is a fully synthetic, orally… 
2011
2011
Human cytochrome P450 and UDP-glucuronosyltransferase reaction phenotyping of MPC-3100, an oral HSP90 inhibitor.
e13019 Background: MPC-3100 is an oral synthetic inhibitor of HSP90, in a phase I safety study in cancer patients. Major… 
2011
2011
Abstract 3233: Comparative in vitro and in vivo metabolism of MPC-3100, an oral HSP90 inhibitor, in rat, dog, monkey and human
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL MPC-3100, an 8, 9-disubstituted purine, is an orally… 
2011
2011
Results of toxicology studies with MPC-3100, an oral HSP90 inhibitor.
e13016 Background: MPC-3100, an orally bioavailable synthetic inhibitor of HSP90, has demonstrated efficacy in animal models and… 
2011
2011
Abstract 2617: MPC-3100, a synthetic Hsp90 inhibitor, induces biomarker changesin vitroand in vivo
Introduction: MPC-3100 is a fully synthetic, orally bioavailable, Hsp90 inhibitor in clinical development. It is broadly active… 
2010
2010
MPC-3100, a fully synthetic, orally bioavailable Hsp90 inhibitor, in cancer patients.
e13112 Background: MPC-3100 is a fully synthetic, orally bioavailable, Hsp90 inhibitor developed by Myriad Pharmaceuticals, Inc… 
2008
2008
150 POSTER MPC-3100: A non-natural product Hsp90 inhibitor with anti-tumor activity in pre-clinical models
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)